Brief: Roche Posts Interim Data Regarding Sefaxersen
BRIEF-Roche Posts Interim Data Regarding Sefaxersen Sept 23 (Reuters) - ROCHE HOLDING AG ROPC.S:
POSITIVE INTERIM DATA SHOWS ROCHE'S SEFAXERSEN SIGNIFICANTLY REDUCES PROTEINURIA IN PEOPLE WITH IGA NEPHROPATHY (IGAN)
INTERIM DATA WILL BE PRESENTED AT AN UPCOMING MEDICAL MEETING AND SHARED WITH HEALTH AUTHORITIES
IN PHASE III IMAGINATION STUDY, SEFAXERSEN DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL REDUCTIONS IN PROTEINURIA VERSUS PLACEBO AT 37 WEEKS, SHOWING BEST-IN-CLASS POTENTIAL
SAFETY AND TOLERABILITY PROFILE OF SEFAXERSEN WAS CONSISTENT WITH PREVIOUSLY REPORTED DATA, WITH NO NEW SAFETY SIGNALS IDENTIFIED
THE STUDY MET ITS PRIMARY ENDPOINT WITH SEFAXERSEN ACHIEVING STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS
Further company coverage: ROPC.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey